Alzamend Neuro is trading 10.68% lower at $1.55, with no clear company-specific catalyst identified for the October 1, 2026 decline. - The latest company announcement located was September 16, when Alzamend Neuro said it had regained Nasdaq listing compliance. - Major U.S. indexes were down only modestly, which does not establish a broad-market explanation for the sharper move.